-The Hindu "We need a relook at the entire approach to development in tribal areas" MALKANGIRI (ODISHA): Abysmally low literacy, high infant mortality rate and inaccessible terrain put a big question mark over the talk of inclusive growth in this tribal-dominated district of Odisha. Considered a hotbed of Maoist activity, the death of 24 children at Potrel and Usakapalli in the Korukonda block and at Charkiguda on the outskirts of the district headquarters...

-The Hindu Close to 100 scientists from across the country and several farmers groups have appealed to the Supreme Court to accept in toto the interim report of the court-appointed Technical Expert Committee (TEC) in the matter of field trials of genetically modified (GM) crops. In its interim report submitted to the court, the panel had recommended a ban on field trials of GM crops until the regulatory system was completely overhauled....

-The Business Standard If the Cabinet clears the proposed policy, the Department of Pharmaceuticals would have to notify this before the SC?s next hearing on the matter on Nov 27 The Cabinet is likely to take up the proposed National Pharmaceutical Pricing Policy tomorrow, government sources said. The policy is aimed at capping the prices of 348 essential Medicines at the weighted average of all drugs in a particular segment, with...

-The Business Standard The move is aimed at having a stringent regulatory system while bringing in uniformity in approach for pricing of drugs  The drug price regulator would now visit manufacturing facilities of pharmaceutical companies while fixing prices of essential Medicines. The National Pharmaceutical Pricing Authority (NPPA) has issued internal guidelines putting in place norms for verification of actual cost data, provided by companies, through plant visits.  The move is aimed at...

-The Hindu Drugs Controller must be told of adverse events within 24 hours Under sharp criticism for inadequate monitoring of clinical trials in the country, the Union Government is contemplating major changes in the Drugs & Cosmetics Act, 1940, and its Rules. These would make it mandatory for the Investigator to report all serious adverse events, including deaths, to the Drugs Controller General of India (DGCI), as well as the sponsor and...